Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sigyn Therapeutics Inc (OP: SIGY )

5.400 UNCHANGED
Last Price Updated: 12:14 PM EST, Nov 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 5.400
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 5.400
Today's Range 5.400 - 5.400
52wk Range 0.1000 - 6.340
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
OTCQB Venture Virtual Investor Conference Presentations Now Available for On-Demand Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
BioMedNewsBreaks — Sigyn Therapeutics Inc. (SIGY) Announces Q1 2024 Financial Results
Via Investor Brand Network
Topics Death
Exposures Death

Performance

YTD
+4053.85%
+4053.85%
1 Month
+12.50%
+12.50%
3 Month
+12.50%
+12.50%
6 Month
+12.50%
+12.50%
1 Year
+2900.00%
+2900.00%

More News

Read More
Sigyn Therapeutics Reports First Quarter 2024 Financial Results
Via NewMediaWire
Sigyn Therapeutics Reports First Quarter 2024 Financial Results
Via TheNewswire.com
BioMedNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Announces Publication of Article on Emerging Candidate – Sigyn Therapy(TM)
Via Investor Brand Network
Topics Death
Exposures COVID-19 Death
Sigyn Therapeutics Discloses Publication of "Sigyn Therapy, an Emerging Candidate to Address Endotoxemia, Sepsis, and Drug-Resistant Viral & Bacterial Infections"
Via NewMediaWire
Exposures COVID-19
BioMedNewsBreaks — Sigyn Therapeutics Inc. (SIGY) Leveraging Portfolio to Overcome Current Limitations in Healthcare
Via Investor Brand Network
Topics Death
Exposures Death
Sigyn Therapeutics Inc. (SIGY) CEO Discusses Company’s Blood Purification Therapies to Address Cancer and Other Life-Threatening Conditions at the Emerging Growth Conference
Via Investor Brand Network
BioMedNewsBreaks — Sigyn Therapeutics Inc. (SIGY) Making Drugs Perform Better
Via Investor Brand Network
Topics Death
Exposures Death
BioMedNewsBreaks — Sigyn Therapeutics Inc. (SIGY) Developing Innovative Technologies to Address Critical Healthcare Challenges
Via Investor Brand Network
Topics Death
Exposures Death
BioMedNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Filling Gap in Therapeutic Antibody Treatment Space
Via Investor Brand Network
Topics Death
Exposures Death
BioMedNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Announces CEO Presentation at Upcoming Emerging Growth Conference
Via Investor Brand Network
Topics Death
Exposures Death
Sigyn Therapeutics to Present at Tomorrow's Emerging Growth Conference
Via NewMediaWire
Sigyn Therapeutics Inc. (SIGY) Therapeutic Candidates to Overcome Limitations in Healthcare
Via Investor Brand Network
Sigyn Therapeutics Inc. (SIGYD) Completes Reverse Stock Split, Releases Year-End Financial Report for 2023
Via Investor Brand Network
Sigyn Therapeutics Announces Filing of 2023 Annual Report on SEC Form 10-K
Via NewMediaWire
Topics Regulatory Compliance
Exposures Legal Regulatory
BioMedNewsBreaks – Sigyn Therapeutics Inc. (SIGY, SIGYD) Announces Implementation of a 1-for-40 Reverse Split
Via Investor Brand Network
Topics Death
Exposures Death
Sigyn Therapeutics Completes Reverse Stock Split
Via NewMediaWire
InvestorNewsBreaks – Sigyn Therapeutics Inc. (SIGY) to Implement 1-for-40 Reverse Split
Via Investor Brand Network
Topics Death
Exposures Death
Sigyn Therapeutics Announces Reverse Stock Split
Via NewMediaWire
Sigyn Therapeutics Announces Reverse Stock Split
Via TheNewswire.com
BioMedNewsBreaks — Why Sigyn Therapeutics Inc. (SIGY) Is ‘One to Watch’
Via Investor Brand Network
Topics Death
Exposures Death
Sigyn Therapeutics Inc. (SIGY) Is ‘One to Watch’
Via Investor Brand Network
BioMedNewsBreaks – Sigyn Therapeutics Inc. (SIGY) CEO Releases Shareholder Letter Outlining Opportunities, Challenges, Processes
Via Investor Brand Network
Topics Death
Exposures Death Product Safety
Sigyn Therapeutics Releases Letter to Shareholders
Via NewMediaWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.